Ilya Glezerman

3.4k total citations · 1 hit paper
64 papers, 1.8k citations indexed

About

Ilya Glezerman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Nephrology. According to data from OpenAlex, Ilya Glezerman has authored 64 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 13 papers in Nephrology. Recurrent topics in Ilya Glezerman's work include Bone health and treatments (10 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Chemotherapy-induced organ toxicity mitigation (9 papers). Ilya Glezerman is often cited by papers focused on Bone health and treatments (10 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Chemotherapy-induced organ toxicity mitigation (9 papers). Ilya Glezerman collaborates with scholars based in United States, France and United Kingdom. Ilya Glezerman's co-authors include Carlos D. Flombaum, Surya V. Seshan, Edgar A. Jaimes, Sheron Latcha, Sujata Patil, Swati Mehta, M Yamashita, F. Stephen Hodi, David E. Leaf and Evan J. Lipson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Ilya Glezerman

56 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

2016 452 citations Ilya Glezerman, David E. Leaf et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ilya Glezerman United States	22	925	508	394	291	231	64	1.8k
Amr El‐Husseini Egypt	24	261 0.3×	290 0.6×	657 1.7×	147 0.5×	177 0.8×	84	1.6k
Masayuki Yamanouchi Japan	23	167 0.2×	405 0.8×	1.0k 2.6×	182 0.6×	449 1.9×	195	2.1k
Nihat Kalay Türkiye	27	969 1.0×	529 1.0×	340 0.9×	203 0.7×	266 1.2×	96	2.6k
David A. Laskow United States	21	402 0.4×	249 0.5×	341 0.9×	62 0.2×	155 0.7×	50	2.1k
Kazuharu Uchida Japan	30	443 0.5×	498 1.0×	1.6k 4.1×	165 0.6×	402 1.7×	191	3.9k
G. Mourad France	23	235 0.3×	256 0.5×	512 1.3×	82 0.3×	218 0.9×	136	1.9k
Tomohiro F. Nishijima Japan	15	1.2k 1.3×	445 0.9×	61 0.2×	224 0.8×	165 0.7×	29	2.3k
Burak Erer Türkiye	20	215 0.2×	234 0.5×	201 0.5×	81 0.3×	632 2.7×	66	1.8k
Erhard Hiller Germany	23	306 0.3×	241 0.5×	109 0.3×	357 1.2×	204 0.9×	96	2.0k
Jens Hammerstrøm Norway	22	266 0.3×	422 0.8×	130 0.3×	138 0.5×	309 1.3×	68	2.5k

Countries citing papers authored by Ilya Glezerman

Since Specialization

Citations

This map shows the geographic impact of Ilya Glezerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilya Glezerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilya Glezerman more than expected).

Fields of papers citing papers by Ilya Glezerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilya Glezerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilya Glezerman. The network helps show where Ilya Glezerman may publish in the future.

Co-authorship network of co-authors of Ilya Glezerman

This figure shows the co-authorship network connecting the top 25 collaborators of Ilya Glezerman. A scholar is included among the top collaborators of Ilya Glezerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilya Glezerman. Ilya Glezerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hensley, Patrick J., Craig Labbate, Jeffrey T. Howard, et al.. (2024). Development and Validation of a Multivariable Nomogram Predictive of Post-Nephroureterectomy Renal Function. European Urology Oncology. 7(6). 1313–1319. 3 indexed citations

Gupta, Shruti, Ilya Glezerman, Jamie S. Hirsch, et al.. (2024). Effect of Intravenous Magnesium on Cisplatin-Associated AKI. Journal of the American Society of Nephrology. 35(10S).

Kelly, Ciara M., et al.. (2022). Thrombotic Microangiopathy Associated With Use of Liposomal Doxorubicin. Journal of the American Society of Nephrology. 33(11S). 384–384.

Seshan, Surya V., et al.. (2021). AKI with BRAF and MEK Inhibitors May Not Be a Class Effect. Journal of the American Society of Nephrology. 32(10S). 579–579.

Bridoux, Frank, Paul Cockwell, Ilya Glezerman, et al.. (2021). Kidney injury and disease in patients with haematological malignancies. Nature Reviews Nephrology. 17(6). 386–401. 22 indexed citations

Salvatore, Steven, et al.. (2020). IgA Nephropathy in the Setting of Dual Immune Checkpoint Inhibitor Use. Journal of the American Society of Nephrology. 31(10S). 669–669.

Dougan, Michael, Ada G. Blidner, Jennifer Choi, et al.. (2020). Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Supportive Care in Cancer. 28(12). 6129–6143. 31 indexed citations

Suarez‐Almazor, María E., Xerxes Pundole, Noha Abdel‐Wahab, et al.. (2020). Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Supportive Care in Cancer. 28(12). 6159–6173. 14 indexed citations

Blidner, Ada G., Jennifer Choi, Tim Cooksley, et al.. (2020). Cancer immunotherapy–related adverse events: causes and challenges. Supportive Care in Cancer. 28(12). 6111–6117. 25 indexed citations

10.

Gutgarts, Victoria, Insara Jaffer Sathick, Junting Zheng, et al.. (2020). Incidence and Risk Factors for Acute and Chronic Kidney Injury after Adult Cord Blood Transplantation. Biology of Blood and Marrow Transplantation. 26(4). 758–763. 11 indexed citations

11.

Shannon, Vickie R., Ronald Anderson, Ada G. Blidner, et al.. (2020). Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Supportive Care in Cancer. 28(12). 6145–6157. 16 indexed citations

12.

Glezerman, Ilya, et al.. (2017). Kidney Toxicities Associated With Novel Cancer Therapies. Advances in Chronic Kidney Disease. 24(4). 233–240. 14 indexed citations

13.

Mendu, Damodara Rao, Lakshmi V. Ramanathan, Melissa S. Pessin, et al.. (2017). Two cases of spontaneous remission of non-parasitic chyluria. Clinical Biochemistry. 50(15). 886–888. 6 indexed citations

14.

Zheng, Jian, Ilya Glezerman, Eran Sadot, et al.. (2017). Hypophosphatemia after Hepatectomy or Pancreatectomy: Role of the Nicotinamide Phosphoribosyltransferase. Journal of the American College of Surgeons. 225(4). 488–497e2. 14 indexed citations

15.

Castillo, Jorge J., Ilya Glezerman, Susan Boklage, et al.. (2016). The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. BMC Cancer. 16(1). 564–564. 63 indexed citations

16.

Castillo, Jorge J., Ilya Glezerman, Susan Boklage, et al.. (2015). Incidence and Prognostic Importance of Hyponatremia in a Cohort of Patients With Lung Cancers. CHEST Journal. 148(4). 552A–552A.

17.

Usui, Joichi, et al.. (2014). Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Human Pathology. 45(9). 1918–1927. 51 indexed citations

18.

Glezerman, Ilya, Tarun Kewalramani, & Komal Jhaveri. (2008). Reversible Fanconi syndrome due to lenalidomide. Clinical Kidney Journal. 1(4). 215–217. 15 indexed citations

19.

Amerling, Richard, et al.. (2003). Interventional Nephrology and Dialysis: Continuous Flow Peritoneal Dialysis: Principles and Applications. Seminars in Dialysis. 16(4). 335–340. 18 indexed citations

20.

Glezerman, Ilya, Hiren Patel, Daniel Glicklich, H Croizat, & Prasad Devarajan. (2003). Angiotensin-Converting Enzyme Inhibition Induces Death Receptor Apoptotic Pathways in Erythroid Precursors following Renal Transplantation. American Journal of Nephrology. 23(4). 195–201. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact